Matches in SemOpenAlex for { <https://semopenalex.org/work/W2964241504> ?p ?o ?g. }
- W2964241504 endingPage "1024" @default.
- W2964241504 startingPage "1024" @default.
- W2964241504 abstract "Hepatocellular carcinoma is often treated with a combination of doxorubicin and embolization, exposing it to high concentrations and hypoxia. Separation of the possible synergistic effect of this combination in vivo is difficult. Here, treatment with doxorubicin, under hypoxia or normoxia in different liver cancer cell lines, was evaluated. Liver cancer cells HepG2, Huh7, and SNU449 were exposed to doxorubicin, hypoxia, or doxorubicin + hypoxia with different duration. Treatment response was evaluated with cell viability, apoptosis, oxidative stress, and summarized with IC50. The protein profile of a 92-biomarker panel was analyzed on cells treated with 0 or 0.1 µM doxorubicin during 6 or 72 h, under normoxia or hypoxia. Hypoxia decreased viability of HepG2 and SNU499. HepG2 was least and SNU449 most tolerant to doxorubicin treatment. Cytotoxicity of doxorubicin increased over time in HepG2 and Huh7. The combination of doxorubicin + hypoxia affected the cells differently. Normalized protein expression was lower for HepG2 than Huh7 and SNU449. Hierarchical clustering separated HepG2 from Huh7 and SNU449. These three commonly used cell lines have critically different responses to chemotherapy and hypoxia, which was reflected in their different protein expression profile. These different responses suggest that tumors can respond differently to the combination of local chemotherapy and embolization." @default.
- W2964241504 created "2019-07-30" @default.
- W2964241504 creator A5077340506 @default.
- W2964241504 creator A5080803089 @default.
- W2964241504 creator A5085118974 @default.
- W2964241504 creator A5088714896 @default.
- W2964241504 creator A5088832801 @default.
- W2964241504 date "2019-07-20" @default.
- W2964241504 modified "2023-10-15" @default.
- W2964241504 title "Liver Cancer Cell Lines Treated with Doxorubicin under Normoxia and Hypoxia: Cell Viability and Oncologic Protein Profile" @default.
- W2964241504 cites W1517771226 @default.
- W2964241504 cites W1543790510 @default.
- W2964241504 cites W1554205984 @default.
- W2964241504 cites W1561366208 @default.
- W2964241504 cites W1700829084 @default.
- W2964241504 cites W1965688832 @default.
- W2964241504 cites W1971837077 @default.
- W2964241504 cites W1971920381 @default.
- W2964241504 cites W1981745506 @default.
- W2964241504 cites W1986087165 @default.
- W2964241504 cites W1999468683 @default.
- W2964241504 cites W2003594637 @default.
- W2964241504 cites W2004602806 @default.
- W2964241504 cites W2007494683 @default.
- W2964241504 cites W2013951470 @default.
- W2964241504 cites W2015454673 @default.
- W2964241504 cites W2019391559 @default.
- W2964241504 cites W2022384547 @default.
- W2964241504 cites W2027271469 @default.
- W2964241504 cites W2032039966 @default.
- W2964241504 cites W2033284075 @default.
- W2964241504 cites W2033520329 @default.
- W2964241504 cites W2035957950 @default.
- W2964241504 cites W2039775393 @default.
- W2964241504 cites W2051740336 @default.
- W2964241504 cites W2058119212 @default.
- W2964241504 cites W2063475020 @default.
- W2964241504 cites W2065939569 @default.
- W2964241504 cites W2066411725 @default.
- W2964241504 cites W2067399963 @default.
- W2964241504 cites W2073858365 @default.
- W2964241504 cites W2075113791 @default.
- W2964241504 cites W2081685920 @default.
- W2964241504 cites W2090404923 @default.
- W2964241504 cites W2106926141 @default.
- W2964241504 cites W2108535196 @default.
- W2964241504 cites W2113001012 @default.
- W2964241504 cites W2121826039 @default.
- W2964241504 cites W2132006978 @default.
- W2964241504 cites W2132066544 @default.
- W2964241504 cites W2133675303 @default.
- W2964241504 cites W2137061905 @default.
- W2964241504 cites W2137499622 @default.
- W2964241504 cites W2143643269 @default.
- W2964241504 cites W2153454059 @default.
- W2964241504 cites W2157945371 @default.
- W2964241504 cites W2217342753 @default.
- W2964241504 cites W2236150109 @default.
- W2964241504 cites W2277004004 @default.
- W2964241504 cites W2328159558 @default.
- W2964241504 cites W2439464730 @default.
- W2964241504 cites W2463195069 @default.
- W2964241504 cites W2470136591 @default.
- W2964241504 cites W2514033550 @default.
- W2964241504 cites W2518446591 @default.
- W2964241504 cites W2531812580 @default.
- W2964241504 cites W2595685820 @default.
- W2964241504 cites W2605668527 @default.
- W2964241504 cites W2612843306 @default.
- W2964241504 cites W2661307008 @default.
- W2964241504 cites W2735127852 @default.
- W2964241504 cites W2755677304 @default.
- W2964241504 cites W2776143999 @default.
- W2964241504 cites W2784709079 @default.
- W2964241504 cites W2790576800 @default.
- W2964241504 cites W2791073714 @default.
- W2964241504 cites W2803624314 @default.
- W2964241504 cites W3022637012 @default.
- W2964241504 cites W4210702584 @default.
- W2964241504 cites W749951569 @default.
- W2964241504 doi "https://doi.org/10.3390/cancers11071024" @default.
- W2964241504 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6678640" @default.
- W2964241504 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31330834" @default.
- W2964241504 hasPublicationYear "2019" @default.
- W2964241504 type Work @default.
- W2964241504 sameAs 2964241504 @default.
- W2964241504 citedByCount "36" @default.
- W2964241504 countsByYear W29642415042019 @default.
- W2964241504 countsByYear W29642415042020 @default.
- W2964241504 countsByYear W29642415042021 @default.
- W2964241504 countsByYear W29642415042022 @default.
- W2964241504 countsByYear W29642415042023 @default.
- W2964241504 crossrefType "journal-article" @default.
- W2964241504 hasAuthorship W2964241504A5077340506 @default.
- W2964241504 hasAuthorship W2964241504A5080803089 @default.
- W2964241504 hasAuthorship W2964241504A5085118974 @default.
- W2964241504 hasAuthorship W2964241504A5088714896 @default.
- W2964241504 hasAuthorship W2964241504A5088832801 @default.